Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging (PARENT-EAR)

4 septembre 2026 mis à jour par: Paula Tähtinen, Turku University Hospital

Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise.

Digital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children.

The PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization.

Methods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant).

Children aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent.

Intervention group:

Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.

Control group:

Standard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice.

Statistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation.

This is a pilot study with a target sample size of 20 children per arm, limited by device availability.

Ethical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest.

The digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis.

Data will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata.

All data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016/679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

40

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Pohjanmaa
      • Vaasa, Pohjanmaa, Finlande, 65130
        • Recrutement
        • Vaasa Central Hospital
        • Contact:
        • Contact:
    • Southwest Finland
      • Turku, Southwest Finland, Finlande, 20521
        • Pas encore de recrutement
        • Turku University Hospital
        • Contact:
        • Contact:
          • Lotta E Ivaska, MD, PhD
          • Numéro de téléphone: +35823130000
          • E-mail: lesaar@utu.fi

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • At least one episode of AOM within the last 12 months
  • Family speaks fluent Finnish

Exclusion Criteria:

  • Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy
  • Middle ear fluid at the time of recruitment
  • Previously diagnosed hearing loss
  • Immunosuppressive disorder or medication, excluding inhaled corticosteroids
  • Anatomic defect or anomaly affecting the susceptibility to AOM
  • Previous otoscopy experience of the participating parent

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Diagnostique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Intervention group
Intervention group to receive the digital otoscope
Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.
Aucune intervention: Control group
Control group with no intervention

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of physician visits due to suspected AOM
Délai: 5 to 9 months, depending on date of recruitment
Number of physician visits due to suspected AOM
5 to 9 months, depending on date of recruitment

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Agreement between parent interpretation, AI classifier, and expert gold standard
Délai: 5 to 9 months, depending on date of recruitment
Parent's interpretation of the tympanic membrane image is retrospectively compared to the expert's gold standard and classification by an artificial intelligence classifier
5 to 9 months, depending on date of recruitment
Antibiotic prescription rates
Délai: 5 to 9 months, depending on date of recruitment
Antibiotic prescription rates for AOM in both arms
5 to 9 months, depending on date of recruitment
Adverse events related to otoscopy
Délai: 5 to 9 months, depending on date of recruitment
Adverse events, such as abrasion, related to otoscopy in the experimental group
5 to 9 months, depending on date of recruitment
AOM-related complications
Délai: 5 to 9 months, depending on date of recruitment
AOM-related complications, such as mastoiditis, in both arms
5 to 9 months, depending on date of recruitment
Daycare absence
Délai: 5 to 9 months, depending on date of recruitment
Child's absence from daycare due to suspected AOM
5 to 9 months, depending on date of recruitment
Parental work absenteeism
Délai: 5 to 9 months, depending on date of recruitment
Parental work absenteeism due to suspected AOM
5 to 9 months, depending on date of recruitment
Parental satisfaction on a visual analog scale (VAS)
Délai: 5 to 9 months, depending on date of recruitment
Parental satisfaction in the experimental group of AOM management with parent-led digital otoscopy
5 to 9 months, depending on date of recruitment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Paula A Tähtinen, MD, PhD, Department of Paediatiatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Finland

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

1 septembre 2026

Achèvement primaire (Estimé)

31 mai 2027

Achèvement de l'étude (Estimé)

31 août 2027

Dates d'inscription aux études

Première soumission

27 mai 2026

Première soumission répondant aux critères de contrôle qualité

6 juin 2026

Première publication (Réel)

10 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • VARHA/4418/13.02.01/2026

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Deidentified participant data will be made available upon reasonable request from the corresponding author.

Délai de partage IPD

Study protocol will be published as supplementary material alongside the study manuscript alongside publication.

Critères d'accès au partage IPD

Deidentified participant data will be made available to fellow researchers upon reasonable request from the corresponding author.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner